Envestnet Asset Management
NAGE

Envestnet Asset Management’s Niagen Bioscience NAGE Stock Holding History

Envestnet Asset Management’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,000
Closed -$144K – 4704
2025
Q2 		$144K Hold
10,000
– – ﹤0.01% 4297
2025
Q1 		$69K Hold
10,000
– – ﹤0.01% 4276
2024
Q4 		$53K Hold
10,000
– – ﹤0.01% 4261
2024
Q3 		$36.5K Hold
10,000
– – ﹤0.01% 4189
2024
Q2 		$27.3K Hold
10,000
– – ﹤0.01% 4134
2024
Q1 		$34.8K Hold
10,000
– – ﹤0.01% 4123
2023
Q4 		$14.3K Hold
10,000
– – ﹤0.01% 4026
2023
Q3 		$14.6K Sell
10,000
-6,005
-38% -$9.38K ﹤0.01% 3988
2023
Q2 		$25.1K Buy
+16,005
New +$23.9K ﹤0.01% 3914

Other funds holding NAGE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Envestnet Asset Management's NAGE Position: Q3 2025 in Review

Envestnet Asset Management sold out of Niagen Bioscience (NAGE) in Q3 2025, closing a stake of 10,000 shares — an estimated $144K sold.

Envestnet Asset Management first reported a position in NAGE in Q2 2023 and held it in 9 quarters. The position peaked at $144K in Q2 2025. 162 funds tracked by Wall St. Rank hold NAGE as of Q3 2025.

  • Envestnet Asset Management reported no remaining Niagen Bioscience position as of Q3 2025 after selling out during the quarter.
  • Envestnet Asset Management sold 10,000 Niagen Bioscience shares in Q3 2025, an estimated $144K.
  • Envestnet Asset Management first reported a position in Niagen Bioscience in Q2 2023 and held it in 9 quarters.
  • Envestnet Asset Management's Niagen Bioscience position peaked at $144K in Q2 2025.
  • 162 funds tracked by Wall St. Rank held Niagen Bioscience as of Q3 2025.

Based on Envestnet Asset Management's 13F filing for Q3 2025, filed 5 Nov 2025.